Using of calcium channel blockers in patients with COVID-19: a magic bullet or a double-edged sword?

Sadeghpopur, Sonia; Ghasemnejad-Berenji, Hojat; Pashapour, Sarvin; Ghasemnejad-Berenji, Morteza

Sadeghpopur, Sonia; Ghasemnejad-Berenji, Hojat; Pashapour, Sarvin; Ghasemnejad-Berenji, Morteza.

Sadeghpopur S; Department of Obstetrics & Gynecology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Ghasemnejad-Berenji H; Department of Anatomy, Histology and Reproductive Biology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pashapour S; Department of Pediatrics, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Ghasemnejad-Berenji M; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran.

J Basic Clin Physiol Pharmacol ; 33(1): 117-119, 2021 Dec 08.

Article in English | MEDLINE | ID: covidwho-1559805

Subject(s)

COVID-19 Drug Treatment; Calcium Channel Blockers; Calcium Channel Blockers/therapeutic use; Humans

Keywords

Ca2+; SARS-CoV-2; amlodipine; anti-inflammatory; antiviral; verapamil

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Calcium Channel Blockers / COVID-19 Drug Treatment Limits: Humans Language: English Journal: J Basic Clin Physiol Pharmacol Journal subject: Pharmacology / Physiology Year: 2021 Document Type: Article Affiliation country: Jbcpp-2021-0334

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google